Age-related Macular Degeneration Market Size, Share, and Growth Analysis, By Product (Eylea & Eylea HD, Lucentis), By Molecule, By Approval Type, By Type of AMD, By End User, By Region - Industry Forecast 2026-2033

Age-related Macular Degeneration Market size was valued at USD 11.29 Billion in 2024 and is poised to grow from USD 12.51 Billion in 2025 to USD 28.42 Billion by 2033, growing at a CAGR of 10.8% during the forecast period (2026-2033).

Age-related macular degeneration (AMD) is a progressive eye condition affecting the central retina, leading to gradual vision loss, primarily in older adults. The condition is classified into two major types: dry and wet AMD, with dry being the more prevalent. While lifestyle modifications and vitamin supplements may help manage dry AMD, wet AMD requires more invasive treatments, typically involving anti-VEGF injections to inhibit the growth of abnormal blood vessels. The global AMD market is expanding, driven by the increasing prevalence of this condition among the aging population and their reliance on medication. Consequently, the rise in patients seeking treatment for AMD suggests a growing market for therapeutic innovations and preventative measures aimed at improving the quality of life for those affected.

Top-down and bottom-up approaches were used to estimate and validate the size of the Age-related Macular Degeneration market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Age-related Macular Degeneration Market Segments Analysis

Global Age-related Macular Degeneration Market is segmented by Product, Molecule, Approval Type, Type of AMD, End User, and region. Based on Product, the market is segmented into Eylea & Eylea HD, Lucentis, Vabysmo, Syfovre, and Other Products. Based on Molecule, the market is segmented into Aflibercept, Faricimab, Ranibizumab, Pegcetacoplan, and Other Molecules. Based on Approval Type, the market is segmented into Biologics, and Biosimilars. Based on Type of AMD, the market is segmented into Wet AMD, and Dry AMD. Based on End User, the market is segmented into Hospitals, Long-Term Care Facilities, Specialty Centers, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Age-related Macular Degeneration Market

The growth of the global age-related macular degeneration (AMD) market is significantly influenced by the rising population of older adults who are more vulnerable to this condition. As life expectancy increases, more individuals face heightened exposure to the risk factors associated with AMD. This trend has resulted in an increased demand for effective therapies and treatments aimed at managing the disease and preventing vision loss. The urgency for solutions to address the challenges posed by AMD ultimately drives innovation and expansion within the market, as both healthcare providers and patients seek to confront the impacts of this age-related vision impairment.

Restraints in the Age-related Macular Degeneration Market

The Age-related Macular Degeneration market faces significant challenges due to inadequate screening and diagnostic processes in certain regions, which adversely affect health outcomes and contribute to treatment delays. Furthermore, a lack of awareness regarding available diagnostic tools hampers market expansion, leading to individuals receiving late interventions. This delay not only limits the potential effectiveness of existing therapies but also exacerbates the overall burden of the disease. Without improved access to timely screenings and a greater understanding of diagnostic options, the market struggles to realize its full potential and provide optimal patient care for those affected by AMD.

Market Trends of the Age-related Macular Degeneration Market

The Age-related Macular Degeneration (AMD) market is witnessing a notable shift towards long-acting therapies, particularly extended-duration anti-VEGF treatments. This trend addresses a critical need for improved patient compliance by reducing the frequency of injections required to manage the condition. By minimizing treatment burdens, these innovations enhance patient experience and outcomes, driving the overall growth of the AMD market. Such advancements not only respond to the challenges faced by previous therapies but also signify a broader movement toward more efficient and patient-friendly treatment modalities, ultimately shaping the future landscape of AMD management.